Posted innews
Evolocumab 预防高风险患者首次发生主要心血管事件
在 VESALIUS-CV 研究中，与安慰剂相比，evolocumab 将无既往心肌梗死或卒中的动脉粥样硬化或糖尿病患者的首次主要不良心血管事件减少了约 25%（HR 0.75），绝对风险降低幅度较小，随访 4.6 年未发现新的安全性信号。
Posted inCardiology Diabetes & Endocrinology news
Evolocumab Prevents First Major Cardiovascular Events in High‑Risk Patients without Prior MI or Stroke
In VESALIUS-CV, evolocumab reduced first major adverse cardiovascular events by ~25% (HR 0.75) versus placebo in patients with atherosclerosis or diabetes without prior myocardial infarction or stroke, with modest absolute risk reductions and no new safety signals over 4.6 years.
Posted inCardiology news
Zalunfiban at First Medical Contact for STEMI: Faster Coronary Patency and Better 30‑Day Outcomes but More Minor Bleeding
In an international randomized trial, subcutaneous zalunfiban given at first medical contact improved pre‑PCI infarct‑related artery patency and reduced the likelihood of a worse 30‑day hierarchical clinical outcome versus placebo, with more mild–moderate bleeding but no increase in severe bleeding.
Posted inClinical Updates news OB/GYN & Women's Health
Elinzanetant: A Novel Non-Hormonal Neurokinin 1 and 3 Receptor Antagonist Transforming Menopausal Vasomotor Symptom Management
Elinzanetant, approved in the UK in July 2025 and by the FDA in October 2025, is the first non-hormonal NK1 and NK3 receptor antagonist for moderate-to-severe menopausal vasomotor symptoms, demonstrated effective and safe in pivotal phase 2b/3 trials with added benefits on sleep and quality of life.
Posted innews OB/GYN & Women's Health
Elinzanetant for Menopausal Hot Flashes: A 52‑Week Phase 3 Trial Shows Modest, Durable Benefit and Acceptable Safety Profile
OASIS‑3 evaluated once‑daily oral elinzanetant 120 mg vs placebo for 52 weeks in postmenopausal women with moderate–severe vasomotor symptoms. At 12 weeks elinzanetant reduced daily moderate–severe VMS frequency by a least‑squares mean difference of −1.6 vs placebo (P < .001); numerical advantages persisted through 50–52 weeks with no signal for hepatotoxicity or endometrial hyperplasia.
Posted inCardiology news Oncology
Managing Heart Risk from Cancer Immunotherapy: The International Cardio-Oncology Society Position on ICI-Associated Cardiovascular Toxicity
An expert summary of the 2025 ICS position statement on immune checkpoint inhibitor–associated cardiovascular toxic effects, with practical diagnostic and treatment guidance for clinicians and researchers.
Posted inCardiology news
Endotyping-informed CMR-guided care markedly improves angina and quality of life in patients with chest pain and no obstructive CAD
A multicenter randomized trial shows stress CMR myocardial perfusion mapping with endotype-directed therapy reclassified diagnosis in 53% of patients with unobstructed coronaries and produced a large, clinically meaningful 21-point improvement in SAQ at 12 months.
Posted inClinical Updates Infectious Diseases news
Elebsiran Combined with Pegylated Interferon Alfa for Chronic Hepatitis B: Advances from Phase 2 Clinical Trials
Phase 2 studies demonstrate that elebsiran, a small interfering RNA, combined with PEG-IFNα, enhances sustained HBsAg loss rates in chronic HBV infection, offering a promising approach toward functional cure.
Posted inNephrology news
Albuminuria Reduction and GFR Total-Slope Strongly Predict Kidney Failure: Surrogate Endpoints in CKD Trials
Large individual-patient meta-analyses show that 6-month albuminuria reduction and 3-year total GFR slope predict kidney failure across CKD populations—supporting their use as surrogate endpoints in randomized trials with caveats for chronic slope and disease severity.
Posted inInfectious Diseases news
Long‑acting Cabotegravir–Rilpivirine Achieves Durable Viral Suppression at 96 Weeks in African CARES Trial: A Practical Leap for HIV Treatment Delivery
The CARES phase 3b trial in Africa found cabotegravir + rilpivirine long‑acting injections every 8 weeks noninferior to continued oral ART for viral suppression at 96 weeks, with an acceptable safety profile and implementation considerations for African programmes.
Tracking Steps to Slow Alzheimer’s: Physical Activity Linked to Reduced Tau Accumulation and Slower Decline in Preclinical AD
In cognitively unimpaired older adults with elevated amyloid, higher daily step counts were associated with slower inferior-temporal tau accumulation and attenuated cognitive and functional decline, with benefit plateauing around 5,000–7,500 steps/day.
Circulating Tumor DNA-Guided Adjuvant Therapy: Recent Advances and Clinical Implications (2021–2025)
This review synthesizes recent evidence (2021–2025) on circulating tumor DNA-guided adjuvant therapy, highlighting advances in personalized cancer management and emerging challenges.
ctDNA-Guided Adjuvant Therapy in Stage III Colon Cancer: DYNAMIC-III Validates Prognosis but Questions Intensification
The randomized phase 2/3 DYNAMIC-III trial shows that postoperative circulating tumor DNA (ctDNA) strongly stratifies recurrence risk in stage III colon cancer. ctDNA-guided de-escalation reduced oxaliplatin exposure and hospitalizations with outcomes close to standard care; escalation for ctDNA-positive disease did not improve recurrence-free survival.
Dual TIGIT/PD‑1 Blockade with Domvanalimab + Zimberelimab Plus FOLFOX Shows Promising Activity in First‑Line Advanced Gastric and GEJ Adenocarcinoma
A phase 2 arm of the EDGE‑Gastric trial reports a 59% confirmed objective response rate and median PFS 12.9 months with domvanalimab (anti‑TIGIT) plus zimberelimab (anti‑PD‑1) combined with FOLFOX in untreated HER2‑negative advanced gastric/GEJ/esophageal adenocarcinoma, with a manageable safety profile.
Posted inHIV/AIDS Infectious Diseases news
Dolutegravir + Lamivudine Is Non‑Inferior to Bictegravir/FTC/TAF for Maintenance Therapy at 48 Weeks: PASO‑DOBLE Randomised Trial
In PASO‑DOBLE, switching virologically suppressed adults to dolutegravir/lamivudine maintained viral suppression at 48 weeks and was non‑inferior to switching to bictegravir/emtricitabine/tenofovir alafenamide, supporting shared decision‑making for maintenance regimen selection.
Posted inClinical Updates HIV/AIDS news
Early Clinical Evaluation of Novel Broadly Neutralising Monoclonal Antibodies for HIV-1: Safety, Pharmacokinetics, and Neutralisation Profiles of N6LS, PGDM1400LS, and PGT121.414.LS
This review summarizes early-phase clinical trials assessing the safety, pharmacokinetics, and neutralisation activity of three innovative broadly neutralising monoclonal antibodies—N6LS, PGDM1400LS, and PGT121.414.LS—for HIV-1 prevention and therapy.
Infant Safety After In-Utero Exposure to Dapivirine Ring or Oral PrEP: 12‑Month Findings from MTN‑042/DELIVER
In a randomized phase 3b trial of pregnant women using the dapivirine vaginal ring or daily oral TDF/FTC for HIV prevention, 12‑month infant follow‑up showed no product‑related serious or grade 3+ adverse events and no HIV transmissions, supporting PrEP use in pregnancy.
Posted inHIV/AIDS news Pediatrics
Once‑Daily Dolutegravir/Lamivudine Fixed‑Dose Tablets Achieve Robust Pediatric Exposures and Reassuring Safety in the D3/PENTA 21 PK Sub‑Study
A nested PK and safety sub‑study of D3/PENTA 21 shows once‑daily DTG/3TC dispersible and film‑coated fixed‑dose tablets deliver adequate drug exposures across WHO weight bands in children 2–<15 years, with no drug‑related discontinuations and comparable PK to historical pediatric data.
Posted innews Oncology Pathology & Lab Medicine
ctDNA-Guided Adjuvant Therapy in Stage III Colon Cancer: Prognostic Validation but No Benefit from Chemotherapy Intensification — Key Findings from the DYNAMIC-III Randomized Phase 2/3 Trial
The DYNAMIC-III trial validates circulating tumor DNA (ctDNA) as a strong prognostic marker in stage III colon cancer. ctDNA-guided de-escalation reduced oxaliplatin exposure and hospitalizations with near-standard outcomes, but escalation for ctDNA-positive patients failed to improve recurrence-free survival.
Dual TIGIT and PD‑1 Blockade with Domvanalimab + Zimberelimab plus FOLFOX Shows Promising Activity in First‑Line Advanced HER2‑Negative Gastroesophageal Adenocarcinoma
In a phase 2 cohort (EDGE‑Gastric A1), domvanalimab (anti‑TIGIT) plus zimberelimab (anti‑PD‑1) combined with FOLFOX produced a 59% ORR, median PFS 12.9 months and median OS 26.7 months in 41 previously untreated HER2‑negative gastroesophageal adenocarcinoma patients, with immune‑related AEs in 27%.
